EPS for Amedisys, Inc. (AMED) Expected At $0.79

October 13, 2018 - By Peter Kolinski

Amedisys, Inc. (NASDAQ:AMED) LogoInvestors sentiment increased to 1.16 in 2018 Q2. Its up 0.03, from 1.13 in 2018Q1. It is positive, as 20 investors sold Amedisys, Inc. shares while 62 reduced holdings. 43 funds opened positions while 52 raised stakes. 29.10 million shares or 7.17% less from 31.35 million shares in 2018Q1 were reported.
Moreover, Deutsche National Bank & Trust Ag has 0.01% invested in Amedisys, Inc. (NASDAQ:AMED). Illinois-based First Limited Partnership has invested 0.01% in Amedisys, Inc. (NASDAQ:AMED). Louisiana State Employees Retirement has 0.05% invested in Amedisys, Inc. (NASDAQ:AMED). Proshare Advsrs Limited Liability Corporation owns 4,693 shares. C M Bidwell And Associate Ltd, Hawaii-based fund reported 1,525 shares. National Bank & Trust Of Mellon reported 702,183 shares stake. Sterling Mngmt Limited Liability Corp holds 0.02% or 23,764 shares. 125,344 are held by Tiaa Cref Invest Management Ltd Liability Co. Public Sector Pension Invest Board holds 18,487 shares or 0.01% of its portfolio. Balyasny Asset Mngmt Limited Liability Com has invested 0.03% in Amedisys, Inc. (NASDAQ:AMED). Wellington Mgmt Gp Ltd Liability Partnership has invested 0.03% in Amedisys, Inc. (NASDAQ:AMED). Eaton Vance Mgmt has invested 0.06% of its portfolio in Amedisys, Inc. (NASDAQ:AMED). Ls Advisors Ltd Liability holds 0.02% of its portfolio in Amedisys, Inc. (NASDAQ:AMED) for 3,449 shares. Adams Diversified Equity Fund holds 9,900 shares or 0.05% of its portfolio. Jpmorgan Chase & invested 0.01% in Amedisys, Inc. (NASDAQ:AMED).

Since May 11, 2018, it had 0 insider buys, and 9 insider sales for $183.27 million activity. Another trade for 11,000 shares valued at $786,708 was sold by North Michael Paul. 3,840 shares were sold by Hall Linda J., worth $309,549 on Wednesday, June 6. Ginn Scott G sold $608,302 worth of stock or 7,755 shares. Kemmerly David L had sold 6,000 shares worth $474,129 on Thursday, June 7. $180.27M worth of Amedisys, Inc. (NASDAQ:AMED) shares were sold by KKR Credit Advisors (US) LLC. Another trade for 398 shares valued at $37,484 was made by Pearce David B. on Wednesday, July 25.

Analysts expect Amedisys, Inc. (NASDAQ:AMED) to report $0.79 EPS on November, 6.They anticipate $0.23 EPS change or 41.07 % from last quarter’s $0.56 EPS. AMED’s profit would be $25.15 million giving it 34.58 P/E if the $0.79 EPS is correct. After having $1.00 EPS previously, Amedisys, Inc.’s analysts see -21.00 % EPS growth. The stock decreased 3.71% or $4.21 during the last trading session, reaching $109.28. About 599,942 shares traded or 61.09% up from the average. Amedisys, Inc. (NASDAQ:AMED) has risen 129.84% since October 13, 2017 and is uptrending. It has outperformed by 114.22% the S&P500.

Amedisys, Inc. (NASDAQ:AMED) Ratings Coverage

Among 5 analysts covering Amedisys (NASDAQ:AMED), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Amedisys had 10 analyst reports since April 17, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, April 17 by SunTrust. The firm earned “Neutral” rating on Tuesday, May 8 by Robert W. Baird. The firm earned “Neutral” rating on Thursday, October 11 by Cantor Fitzgerald. The stock of Amedisys, Inc. (NASDAQ:AMED) has “Neutral” rating given on Tuesday, June 5 by Robert W. Baird. The firm earned “Neutral” rating on Tuesday, June 5 by Bank of America. Bank of America maintained the stock with “Buy” rating in Tuesday, September 18 report. The rating was upgraded by Bank of America on Tuesday, July 3 to “Buy”. On Thursday, October 11 the stock rating was maintained by Robert W. Baird with “Neutral”.

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. The company has market cap of $3.48 billion. It operates through three divisions: Home Health, Hospice, and Personal Care. It has a 52.79 P/E ratio. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

More important recent Amedisys, Inc. (NASDAQ:AMED) news were published by: Seekingalpha.com which released: “Amedisys Is A Solid Buy Opportunity In 2018” on September 17, 2018, also Globenewswire.com published article titled: “Amedisys Extends Employment Agreement with CEO Paul Kusserow”, Globenewswire.com published: “Amedisys Signs Definitive Agreement to Acquire Compassionate Care Hospice” on October 10, 2018. More interesting news about Amedisys, Inc. (NASDAQ:AMED) was released by: Globenewswire.com and their article: “Amedisys Closes on Massachusetts Personal Care Acquisition” with publication date: October 02, 2018.

Amedisys, Inc. (NASDAQ:AMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>